All news from R&D

Early Clinical Trial Access: Barriers Still Exist

Young cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congress in Munich, you have highlighted the existence of barriers to the inclusion of 12 to 25-year-olds in both adult and early childhood clinical trials, suggesting a need for more tailored approaches to give this patient population better access to therapeutic innovation.

Clinical Trials of Functional Engineered Oesophagus In-Process

The world's first functional oesophagus engineered from stem cells has been grown and successfully transplanted into mice, as part of a pioneering new study led by UCL. It was hoped this research, carried out by UCL Great Ormond Street Institute of Child Health (ICH), in collaboration with Great Ormond Street Hospital (GOSH) and the Francis Crick Institute, could pave the way for clinical trials of lab-grown food pipes for children with congenital and acquired gut conditions.

Biosensor Advances Diverse High-level Production of Microbial Cell Factories

A research group presented a novel biosensor which can produce diverse, high-level microbial cell factories. The biosensor monitors the concentration of products and even intermediates when new strains are being developed. This strategy provides a new platform for manufacturing diverse natural products from renewable resources. The team succeeded in creating four natural products of high-level pharmaceutical importance with this strategy.

Promising Routes for Research: Novel Method using Big Data Tools

A group of researchers affiliated to the University of São Paulo (USP) – campus Ribeirão Preto, Brazil, used big data tools such as data mining and network analysis to develop a method to help scientists and companies identify technological routes, trends and partnerships in any knowledge area. For this purpose, it collected information from patent databases around the world.

ARRIVE Trial: Daily Aspirin Does not Reduce Risk of First Cardiovascular Event

The role of aspirin in preventing a first heart attack or stroke among people at moderate risk of heart disease remains unclear. At the 2018 European Society of Cardiology meeting, J. Michael Gaziano presented findings from ARRIVE, a randomized, controlled clinical trial of the use of daily aspirin to prevent a first cardiovascular event among more than 12,500 participants considered to be at moderate cardiovascular risk. The team's findings are detailed in a paper published simultaneously in The Lancet.